IP Library Granted Patent US 9,260,510
Granted Patent B2
US 9,260,510 · App. 14/135,353 · Granted Feb 16, 2016

Pertussis antibodies and uses thereof

Inventors: Jennifer A. Maynard (Austin, TX); Jamie Sutherland (Austin, TX)
Assignee: Board of Regents, The University of Texas System
C07K16/1225C07K2317/24C07K2317/55C07K2317/622C07K2317/76C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,260,510
App. No.
14/135,353
Granted
Feb 16, 2016
Kind
B2
Abstract

Compositions and methods are provided that are useful to treat respiratory diseases such as whooping cough. Further, compositions and methods of immunizing are provided.

Claims (12)

1. A humanized mouse 1B7 antibody capable of binding a pertussis toxin protein, the humanized antibody comprising a humanized heavy chain and a humanized light chain, wherein said humanized light chain comprises a phenylalanine at a position corresponding to Kabat position 65, a mouse CDR L1 as set forth in SEQ ID NO:3, a mouse CDR L2 as set forth in SEQ ID NO:4, and a mouse CDR L3 as set forth in SEQ ID NO:5; and

wherein said humanized heavy chain comprises a mouse CDR H1 as set forth in SEQ ID NO:6, a mouse CDR H2 as set forth in SEQ ID NO:7 and a mouse CDR H3 as set forth in SEQ ID NO:8.

2. The humanized mouse 1B7 antibody of claim 1 , wherein the antibody is a Fab′ fragment.

3. The humanized mouse 1B7 antibody of claim 1 , wherein the antibody comprises a human constant region.

4. The humanized mouse 1B7 antibody of claim 1 , wherein the antibody is an IgG.

5. The humanized mouse 1B7 antibody of claim 1 , wherein the antibody is a single chain antibody (scFv).

6. The humanized mouse 1B7 antibody of claim 1 , wherein the antibody is capable of binding said pertussis toxin protein with an equilibrium dissociation constant (K D ) less than 10 nM.

7. The humanized mouse 1B7 antibody of claim 6 , wherein said pertussis toxin protein is a truncated pertussis toxin protein.

8. The humanized mouse 1B7 antibody of claim 7 , wherein said truncated pertussis toxin protein comprises the amino acid sequence corresponding to amino acid residues 1 to 220 of SEQ ID NO:9.

9. The humanized mouse 1B7 antibody of claim 6 , wherein the humanized antibody is an antibody which competes with an antibody that is capable of binding a pertussis toxin protein comprising the amino acid sequence corresponding to amino acid residues 1 to 220 of SEQ ID NO:9.

10. A pharmaceutical composition comprising a therapeutically effective amount of a humanized mouse 1B7 antibody as set forth in claim 1 .

11. A method of treating whooping cough in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a humanized mouse 1B7 antibody as set forth in claim 1 .

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 4, 2015
From: UNIVERSITY OF TEXAS, AUSTIN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035828/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2014
From: MAYNARD, JENNIFER A.; SUTHERLAND, JAMIE
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 033346/0513 →
Continuity (3)
Continuation 13236530 · Sep 19, 2011
Provisional Application 61384104 · Sep 17, 2010
Related Publication 20140193401A1 · Jul 10, 2014